RT @Tevogen: 📰 globenewswire.com/news-release/2…
Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement
Up to $28.6 million in…
Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement
Up to $28.6 million in…
0
6
0
1
RT @Tevogen: 📰 globenewswire.com/news-release/2…
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
🔹Both previousl…
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
🔹Both previousl…
0
5
0
3
RT @Tevogen: 📰 globenewswire.com/news-release/2…
Tevogen is a healthcare enterprise focused on improving the affordability and accessibility of life…
Tevogen is a healthcare enterprise focused on improving the affordability and accessibility of life…
0
6
0
2
RT @TevogenBio: Tevogen Bio Announces 2026 Annual Meeting of Stockholders
📰 globenewswire.com/news-release/2…
The Annual Meeting will be held virtu…
📰 globenewswire.com/news-release/2…
The Annual Meeting will be held virtu…
0
5
0
3
RT @Tevogen: Tevogen Bio Announces 2026 Annual Meeting of Stockholders
📰 globenewswire.com/news-release/2…
The Annual Meeting will be held virtuall…
📰 globenewswire.com/news-release/2…
The Annual Meeting will be held virtuall…
0
6
0
6
RT @DrRyanSaadi: The most powerful pharmacy in the world isn’t on a street corner. It’s already inside our veins. @TevogenBio - #Tcell
🌐 h…
🌐 h…
0
5
0
RT @TevogenBio: 📰 globenewswire.com/news-release/2…
“Tevogen’s evaluation of potential MSO and CRO acquisitions reflects a disciplined approach to b…
“Tevogen’s evaluation of potential MSO and CRO acquisitions reflects a disciplined approach to b…
0
4
0
RT @TevogenBio: “Bridging medical science and artificial intelligence to develop affordable, lifesaving therapies isn’t just innovation, it…
0
3
0
RT @TevogenBio: At JPM43 Mittul Mehta, @Head_TevogenAI and @drhew
Chief Medical Officer & VP of Healthcare at
@Microsoft discussed AI in Bi…
Chief Medical Officer & VP of Healthcare at
@Microsoft discussed AI in Bi…
0
4
0
RT @TevogenBio: 📰 globenewswire.com/news-release/2…
“Advancing PredicTcell toward completion marks an important milestone in our AI strategy,” said…
“Advancing PredicTcell toward completion marks an important milestone in our AI strategy,” said…
0
4
0
RT @TevogenBio: 🔗 databricks.com/blog/tevogen-b…
As part of our ongoing work on PredicTcell™, we’ve been leveraging scalable data infrastructure…
As part of our ongoing work on PredicTcell™, we’ve been leveraging scalable data infrastructure…
0
4
0
RT @TevogenBio: Tevogen.AI at @FABConSQLCon
Tevogen CIO and @Head_TevogenAI, Mittul Mehta, speaking to building an AI-ready d…
Tevogen CIO and @Head_TevogenAI, Mittul Mehta, speaking to building an AI-ready d…
0
3
0
Tevogen AI retweeted
Honored to see Tevogen.AI recognized by @Microsoft at #FabCon as an ISV. AI in biotech is shifting from models to systems—continuous learning, real-world feedback, and scale. Just getting started. #AI #Biotech $TVGN $MSFT @arunulag
0
4
4
477
Tevogen AI retweeted
📰 globenewswire.com/news-release/2…
@Head_TevogenAI Mittul Mehta, stated, “Our goal is to reduce trial-and-error in immunotherapy design and ultimately predict the proteome for any given combination of protein and HLA type. As our prediction quality improves, we believe we can uccess rates while lowering development risk. That combination has the potential to create significant long-term value.”
@TevogenAI $TVGN #PredicTcell #artificialintelligence #DrugDiscovery #immunotherapy
@Head_TevogenAI Mittul Mehta, stated, “Our goal is to reduce trial-and-error in immunotherapy design and ultimately predict the proteome for any given combination of protein and HLA type. As our prediction quality improves, we believe we can uccess rates while lowering development risk. That combination has the potential to create significant long-term value.”
@TevogenAI $TVGN #PredicTcell #artificialintelligence #DrugDiscovery #immunotherapy
0
3
5
316
RT @Tevogen: 📰 globenewswire.com/news-release/2…
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care…
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care…
0
4
0
Tevogen AI retweeted
📢 From Mittul Mehta, Tevogen CIO and @Head_TevogenAI.
Most companies celebrate going public. We used it as a starting gun.
Two years ago, Tevogen went public at Nasdaq - A day I’ll always remember for the energy, the optimism, and the responsibility that comes with running a the morning after, the real work began.
When we stood up Tevogen.AI, the conviction was clear: AI wasn't going to be a support function. It was going to be a frontier capability that fundamentally changed how we read, understand, and act on complex biological data.
Simple in conviction. Hard in execution.
Since then, the teams have gone from thesis to tangible: 655 million unique peptides, models scaling nearly 20x between training cycles, and a platform built to compound as the science advances. None of that came from moving fast for its own sake. It came from disciplined decisions — what to build, what to buy, and where partnerships produced durable leverage.
What excites me most isn't what's already been achieved… It's what's next.
As we close out beta training for PredicTcell™ and move into AdapTcell™, the platform is transitioning from experimentation to operational reality. The feedback loop between our AI and biology teams is tightening with every cycle and increasing learning velocity.
Two years on, the work feels less about celebration and more about momentum, which is exactly where it should be.
For leaders building AI at scale: where are you seeing the biggest gap between experimentation and execution?
#AIinBiotech #LifeSciences #TechnologyStrategy #Leadership $TVGN #Board #CIO #AIPlatforms #PublicCompany #BoardPerspective #TechnologyLeadership
Most companies celebrate going public. We used it as a starting gun.
Two years ago, Tevogen went public at Nasdaq - A day I’ll always remember for the energy, the optimism, and the responsibility that comes with running a the morning after, the real work began.
When we stood up Tevogen.AI, the conviction was clear: AI wasn't going to be a support function. It was going to be a frontier capability that fundamentally changed how we read, understand, and act on complex biological data.
Simple in conviction. Hard in execution.
Since then, the teams have gone from thesis to tangible: 655 million unique peptides, models scaling nearly 20x between training cycles, and a platform built to compound as the science advances. None of that came from moving fast for its own sake. It came from disciplined decisions — what to build, what to buy, and where partnerships produced durable leverage.
What excites me most isn't what's already been achieved… It's what's next.
As we close out beta training for PredicTcell™ and move into AdapTcell™, the platform is transitioning from experimentation to operational reality. The feedback loop between our AI and biology teams is tightening with every cycle and increasing learning velocity.
Two years on, the work feels less about celebration and more about momentum, which is exactly where it should be.
For leaders building AI at scale: where are you seeing the biggest gap between experimentation and execution?
#AIinBiotech #LifeSciences #TechnologyStrategy #Leadership $TVGN #Board #CIO #AIPlatforms #PublicCompany #BoardPerspective #TechnologyLeadership
0
3
5
351
RT @TevogenBio: 📰 globenewswire.com/news-release/2…
“Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare c…
“Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare c…
0
3
0
RT @TevogenBio: 📢 From Mittul Mehta, Tevogen CIO and Head of @TevogenAI
Reflecting on the past year at Tevogen.AI, I’m proud…
Reflecting on the past year at Tevogen.AI, I’m proud…
0
5
0
Tevogen AI retweeted
🎙Q&A with Tevogen CEO🎙
Q. As Tevogen continues to build long-term value, how do you think about capital allocation and sharing that success with shareholders over time?
A. I’ve always believed that when a company succeeds, shareholders should share in that success. I am suppluating a potential one-time special cash dividend in the context of future performance, which is obviously subject to Board approval. I personally believe returning capital to shareholders is critical for long term value creation for any high growth enterprise. - @DrRyanSaadi
$TVGN #affordable #accessible #celltherapy #JPM2026 @Tevogen @TevogenAI
Q. As Tevogen continues to build long-term value, how do you think about capital allocation and sharing that success with shareholders over time?
A. I’ve always believed that when a company succeeds, shareholders should share in that success. I am suppluating a potential one-time special cash dividend in the context of future performance, which is obviously subject to Board approval. I personally believe returning capital to shareholders is critical for long term value creation for any high growth enterprise. - @DrRyanSaadi
$TVGN #affordable #accessible #celltherapy #JPM2026 @Tevogen @TevogenAI
0
3
8
1,261